当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2008年第15期
编号:11620670
抗VEGF治疗眼新生血管性疾病(1)
http://www.100md.com 2008年7月22日 《中国医药导报》 2008年第15期
     [摘要] 新生血管形成是很多重要眼部疾病的共同病理改变,血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)是新生血管形成过程中的关键性因子。近年来,抗VEGF药物的出现给新生血管性眼病的治疗开辟了新的途径。本文就近年来抗VEGF制剂在眼部新生血管性疾病的应用和副作用方面予以综述。

    [关键词] 新生血管性眼病; VEGF;治疗;副作用

    [中图分类号] R771[文献标识码]A [文章编号]1673-7210(2008)05(c)-028-03

    Anti-VEGF therapies for ocular neovascular disease

    LUO Ling , ZHANG Mao-nian

    (Department of Ophthalmology, the General Hospital of PLA, Beijing 100853,China)

    [Abstract] Angiogenesis is the main pathologic characters in many important ocular diseases. Vascular endothelial growth factor has been identified as playing a key role in ocular angiogenesis. In recent years, anti-VEGF therapies have shown unprecedented efficacy in treating ocular neovascular disease. This review will focus on the anti-VEGF for the current treatment of ocular neovascular disease and its side effects.

    [Key words] Ocular neovascular disease;VEGF;Treatment;Side effects

    眼新生血管形成是很多眼部疾病的共同病理改变 ......
1 2 3下一页

您现在查看是摘要页,全文长 4680 字符